ScreenerHero

CBIOCatalyst Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · crescentbiopharma.com
17.15USD-0.98%Mkt Cap: 637.02M $P/E: —

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VE…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap637.02M $
Enterprise Value528.51M $
Revenue (TTM)11.88M $
Gross Profit11.88M $
Net Income (TTM)-153.94M $
Revenue/Share0.4340 USD
Last Price17.15 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees69
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINIE0004LIBFM2
Valuation
P/E (Trailing)—
P/E (Forward)-6.17
PEG—
EV/EBITDA-3.11
EV/Revenue44.48
P/S50.73
P/B3.41
EPS (TTM)-0.13
EPS (Forward)-2.63
52W Range
8.72045% of range27.41
52W High27.41 USD
52W Low8.720 USD
Profitability
Gross Margin100.00%
Oper. Margin-1432.63%
EBITDA Margin0.00%
Profit Margin-1419.61%
ROE-75.83%
ROA-64.06%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-71.53M $
CapEx (TTM)72.92M $
FCF Margin—
FCF Yield—
Net Debt-170.16M $
Net Debt/EBITDA1.00
Balance Sheet
Debt/Equity0.01
Current Ratio9.66
Quick Ratio9.26
Book Value/Sh4.766 USD
Cash/Share4.009 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateJun 16, 2025
Analyst Consensus
Rating—
Target (Mean)30.60 USD
Upside (mean)+78.4%
Target Range27.00 USD – 35.00 USD
$27.00+78.4% to mean$35.00
# Analysts5
Ownership
Shares Out.37.14M
Float26.63M
Insiders0.42%
Institutions82.15%
Short Interest
Short Ratio8.9d
Short % Float16.01%
Short % Out.9.33%
Shares Short3.47M
Short (prev mo.)3.67M
Technical
SMA 5016.72 (+2.6%)
SMA 20015.17 (+13.0%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)331.19K
Avg Vol (10d)165.93K
Technical Indicators
RSI (14)53.8
MACD0.1697
MACD Signal-0.0283
MACD Hist.+0.1980
BB Upper18.21 USD
BB Middle16.37 USD
BB Lower14.53 USD
BB Width22.43%
ATR (14)1.148 USD
Vol Ratio (20d)0.93x